Ready to start planning your care? Call us at 800-525-2225 to make an appointment.





Make an Appointment

Tangible Materials Available for Licensing Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

I his cell line was established in 1975 from a recurrent melanoma at the apex of the left axilla of a 19-yearold Caucasian male.

Inventors

Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research

Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

Carey TE et al. (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. *Proceedings of the National Academy of Sciences* 73: 3278-3282 (Pubmed ID: 1067619)

Lau YS et al. (2006) Malignant melanoma and bone resorption. *British Journal of Cancer* 94(10): 1496-1503 (PubMed ID: 16641914)

Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. *Oncogene* 31(4): 446-457 (Pubmed ID: 21725359)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, <u>646-888-1078</u>, <u>bugaa@mskcc.org</u>

For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, <u>646-888-2354</u>, <u>weisgarf@mskcc.org</u>

Stage of Development

Ready to use

Indications

Cancer > Melanoma

Types

Research Tools > Cell Lines

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility statement

Privacy policy

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center